Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.

Antimicrobial Agents and Chemotherapy
J ChildR Wise

Abstract

Two levofloxacin administration regimens were used for six healthy male volunteers. They received either 500 mg of levofloxacin orally every 12 h for five doses or 500 mg every 24 h for three doses, and then 6 weeks later they received the other course. The concentrations of the drug in plasma, cantharidin-induced inflammatory fluid, and urine were measured with a microbiological assay following administration of the final dose. Mean peak concentrations in plasma of 9.3 and 6.6 micrograms/ml were attained 1.1 and 1.2 h after the 12- and 24-h regimens, respectively. Mean peak concentrations is inflammatory fluid of 6.8 and 4.3 micrograms/ml were attained at 2.3 and 3.7 h, respectively. The average steady-state concentrations were 5.0 and 2.2 micrograms/ml in plasma and 4.7 and 2.3 micrograms/ml in inflammatory fluid, respectively. The mean terminal elimination half-lives for plasma were 7.9 and 8.0 h for the two regimens, respectively, and the same values were noted for inflammatory fluid. The overall penetration into inflammatory fluid ranged from 88 to 101% with the 12-h regimen and 83 to 112% with the 24-h regimen. Mean urinary recoveries were 87 and 86% over the corresponding interval of the 12- and 24-h regimens, respective...Continue Reading

References

Nov 1, 1992·Antimicrobial Agents and Chemotherapy·J H JohnsonR Wise
Apr 1, 1992·Antimicrobial Agents and Chemotherapy·K P FuM E Rosenthale
Feb 7, 1991·The New England Journal of Medicine·D C Hooper, J S Wolfson
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·K NyeR Wise
Nov 1, 1986·The Journal of Antimicrobial Chemotherapy·J T Smith
Mar 1, 1966·Applied Microbiology·J V BennettW M Kirby
Jul 1, 1980·The Journal of Infectious Diseases·R WiseS Baker
Apr 1, 1994·Antimicrobial Agents and Chemotherapy·S D GoodwinJ A Bartlett
Apr 1, 1994·Antimicrobial Agents and Chemotherapy·N DholakiaG P Bodey
Dec 1, 1993·Antimicrobial Agents and Chemotherapy·S A Marshall, R N Jones

❮ Previous
Next ❯

Citations

May 1, 1996·Diagnostic Microbiology and Infectious Disease·D J Biedenbach, R N Jones
Mar 29, 2001·Journal of Pharmaceutical and Biomedical Analysis·S BöttcherH G Sonntag
Nov 3, 2001·International Journal of Antimicrobial Agents·H von BaumH G Sonntag
Apr 27, 2002·Journal of Clinical Pharmacy and Therapeutics·A T ChowR R Williams
Jun 25, 1999·The Journal of Antimicrobial Chemotherapy·P D Lister, C C Sanders
Jul 18, 2000·Antimicrobial Agents and Chemotherapy·G L DrusanoJ Kahn
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Keith A RodvoldMark H Gotfried
May 27, 2005·Antimicrobial Agents and Chemotherapy·Jeffrey J CampionMartin E Evans
Oct 20, 2001·Pharmacotherapy·K A Rodvold, M Neuhauser
May 1, 2001·Clinical Pharmacokinetics·A AminimanizaniR Jelliffe
Jan 23, 1999·Clinical Therapeutics·S M WimerM W Garrison
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S R Norrby
Jun 7, 2008·International Journal of Antimicrobial Agents·Thomas TsaganosKyriaki Kanellakopoulou
Jul 30, 2005·Journal of Veterinary Pharmacology and Therapeutics·G A AlbarellosM F Landoni
Nov 13, 2008·Journal of Veterinary Pharmacology and Therapeutics·A GoudahA M Abd El-Aty
Apr 9, 1998·The Annals of Pharmacotherapy·S J MartinS L Pendland
Jul 1, 2018·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Dragana D BožićIvana Ćirković
May 21, 1998·Antimicrobial Agents and Chemotherapy·G A PankuchP C Appelbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.